Lori Anne Kunkel - 06 Jul 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: Director
Issuer ticker: ELVN
Reported as of: 06 Jul 2026
Net transaction value: -$504,903
SEC form: 4
Accepted by SEC: 08 Jul 2026, 17:15:48 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

Lori Anne Kunkel filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 08 Jul 2026.

Key facts

This page summarizes Lori Anne Kunkel's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Jul 2026, 17:15.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: -$504,903.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001536368 Primary reporting owner

Kunkel Lori Anne

Relationship: Director
Address: C/O ENLIVEN THERAPEUTICS, INC., 205 PARK ROAD, BURLINGAME
Signature: /s/ Ben Hohl, by power of attorney
Signature date: 08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Sale

Transaction value: $205,482
Shares: -4,111
Change %: -7.9%
Price: $49.98
Shares after: 47,773
Date: 06 Jul 2026
Ownership: Direct
Footnotes: F1, F2

ELVN transaction

Common Stock

Sale

Transaction value: $299,421
Shares: -5,889
Change %: -12%
Price: $50.84
Shares after: 41,884
Date: 06 Jul 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026

Footnote F2

This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.